Hence, these findings may provide a new insight into EXT1 as a promising novel therapeutic target for overcoming breast cancer stemness and chemoresistance in breast cancer patients with anthracycline-based therapeutic resistance. This evidence concerns the gene EXT1 and breast carcinoma.